Previous reporters have shown that ribavirin could be clinically beneficial as antitumor agent in patients with poor AML prognosis characterized by elevated eIF4E with no significant treatment-related toxicity [3]. This evidence concerns the gene EIF4E and acute myeloid leukemia.